Banco Master Scandal: Allegations of Favoritism and Influence in Brazil’s Insulin Contracts
By Hotspotnews
The Banco Master scandal has become one of the most explosive controversies in Brazil in recent years, intertwining high finance, government contracts, judicial connections, and accusations of favoritism and influence-peddling. At its core is Daniel Vorcaro, the former controlling figure of Banco Master, a mid-sized bank that collapsed dramatically in late 2025 after the Central Bank ordered its extrajudicial liquidation due to severe liquidity problems, alleged fraud, and operations involving billions in questionable credit instruments.
Vorcaro was arrested while trying to leave the country, facing charges related to a massive fraud scheme that artificially inflated the bank’s balance sheet. The fallout has exposed a network of relationships involving political figures, ex-ministers, and even relatives of Supreme Court justices. A major flashpoint is the claim that Biomm—a biotechnology company in which Vorcaro (through Banco Master and related funds) held a significant stake of around 25-26%—secured substantial government contracts for insulin supply under President Lula’s administration.
### The Insulin Contracts: What Happened
Biomm, a publicly traded Brazilian biotech firm focused on diabetes treatments, entered into Productive Development Partnerships (PDPs) with the Ministry of Health, involving technology transfer and local production of insulin. These partnerships included collaborations with international partners like the Chinese firm Gan & Lee Pharmaceuticals and Brazilian public institutions such as Fiocruz/Bio-Manguinhos.
Key deals signed in 2025 included:
– A June 2025 contract worth approximately R$142 million for supplying human insulin to the SUS (Brazil’s public health system), with a one-year delivery period under a partnership involving Biomm, Wockhardt, and Fundação Ezequiel Dias.
– A November 2025 contract valued at around R$131 million (initial amount) for insulin glargine supply, tied to a longer-term PDP with Gan & Lee and Fiocruz, aiming for localized production of millions of vials annually to reduce import dependency and benefit diabetes patients in the public system.
These agreements totaled at least R$303.65 million in disclosed commitments. The PDPs are structured as public-private initiatives to build national pharmaceutical capacity, with goals like delivering 20 million vials of glargine by certain targets and eventually achieving higher local market share.
### Where the Alleged Wrongdoing Lies
Critics argue the potential misconduct is not necessarily in the existence of the contracts themselves (which address a legitimate public health need after decades without domestic insulin production), but in the surrounding circumstances that suggest favoritism, undue influence, and conflicts of interest. Here’s a breakdown of the main points of contention:
1. **Vorcaro’s Ownership Stake and Timing**
Banco Master (controlled by Vorcaro) was the largest shareholder in Biomm via funds like Cartago. The insulin contracts were awarded months after Vorcaro’s personal access to top government officials, raising suspicions that his connections helped secure or expedite the deals for a company in which he had a major financial interest. Opponents claim this constitutes favoritism—directing public funds to a connected private entity rather than through fully competitive, transparent processes—potentially violating rules on impartiality in public procurement and anti-corruption statutes.
2. **The Off-the-Record Meeting with President Lula**
In December 2024, Vorcaro met President Lula at the Planalto Palace in a gathering not listed on official schedules. The meeting—lasting about 90 minutes—included then-Central Bank nominee Gabriel Galípolo, Minister Alexandre Silveira (Mines and Energy), and former Finance Minister Guido Mantega (who reportedly arranged it and received high monthly consulting fees from Master-linked entities). Vorcaro discussed banking issues and liquidity challenges facing his institution.
The lack of transparency (no agenda entry, no GSI log for that specific visit despite other recorded Planalto entries by Vorcaro in prior years) creates the appearance of privileged, back-channel access. Critics argue this could indicate attempts to secure government support or leniency for the bank—or, by extension, benefits for Vorcaro’s broader business interests, including Biomm—amounting to improper lobbying or influence-peddling.
3. **Financial Ties to Judicial and Political Figures**
Banco Master reportedly paid substantial sums to entities connected to powerful figures:
– Contracts with the law office of Ricardo Lewandowski (former Supreme Court justice and later Justice Minister) totaling millions (around R$250,000 monthly initially, later transferred to family members).
– A high-value agreement (up to R$129 million over time, with large monthly payments) linked to the office of Viviane Barci de Moraes, wife of Supreme Court Justice Alexandre de Moraes.
– Investments and structures involving family members of Justice Dias Toffoli (e.g., luxury resort ties through funds and relatives).
– Consulting fees to Guido Mantega (around R$1 million monthly).
These arrangements raise serious concerns of **influence-peddling** and conflicts of interest. Paying large sums to relatives or associates of sitting justices (who may handle related cases) or ex-officials who facilitate access to the executive branch can undermine judicial impartiality and public trust. It potentially breaches ethics rules prohibiting participation in matters involving personal or familial financial interests, and fuels accusations that such payments bought protection, favorable rulings, or political goodwill.
### Defenses and Current Status
Government allies and involved parties maintain that the Biomm contracts followed standard PDP procedures focused on health sovereignty and were not influenced by Vorcaro personally (Biomm has stated it has no direct operational ties to him or the bank). The Lula meeting is described by some as routine discussion without improper intent, and judicial consultancies are portrayed as legitimate pre-government or private activities. No final court ruling has yet proven direct illegality linking the insulin deals to corruption.
Investigations by federal police continue, alongside political pressure for a congressional inquiry (CPI). The scandal highlights broader systemic risks in Brazil: opaque access to power, blurred lines between business and politics, and the vulnerability of public contracts when personal networks dominate.
Whether proven criminal acts or merely poor optics, the case underscores how concentrated influence among elites can erode confidence in institutions—especially when public money for essential medicines becomes entangled in elite financial dramas.